Rezolute Completes Enrollment of its Phase 2 Study in Diabetic Macular Edema (“DME”)

<p>Plans to report topline data mid-second quarter 2024 REDWOOD CITY, Calif., Dec. 13, 2023 (GLOBE NEWSWIRE) — Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare diseases, today announced the completion of enrollment in its RZ402 Phase 2 study in diabetic macular edema (“DME”). RZ402 is a […]</p>
<p>The post <a href="https://forextv.com/top-news/rezolute-completes-enrollment-of-its-phase-2-study-in-diabetic-macular-edema-dme/">Rezolute Completes Enrollment of its Phase 2 Study in Diabetic Macular Edema (“DME”)</a> appeared first on <a href="https://forextv.com">ForexTV</a>.</p>